Virttu Biologics Limited a UK biotechnology company with expertise in thefield of oncolytic viruses reports that it has received a Notice of Allowance from the US Patent and Trade Mark Office in respect of US patent application 12/436,382 and Virttu expects the patent to be issued in the fourth quarter 2013.
26 June, 2013
Sanofi and the Curie Institute have announced a three-year research collaboration to identify new therapeutic targets for the treatment of ovarian cancer.
21 June, 2013
Cancer Research Technology, the commercial arm of Cancer Research UK, the University of Manchester and AstraZeneca today announced two agreements to seek new cancer drugs.
17 June, 2013
A national research facility has opened which will put the UK at the forefront of a revolution in health and medical research. The MRC-NIHR Phenome Centre will examine around one hundred thousand blood and urine samples every year. It will analyse phenomes – the biological results of people's genes and environment – to help determine the causes of disease and indicate how treatments can be tailored for individual patients.
10 June, 2013
A GBP250k prize is being offered to encourage researchers to deliver a breakthrough in toxicology research that could ultimately lead to the replacement of animals used in product safety testing.
06 June, 2013
MRC Technology, a technology transfer organisation, announced today the presentation of positive data for lambrolizumab, initially advanced by MRC Technology’s antibody engineering group, at the American Society for Clinical Oncology meeting in Chicago. The study is also published online in the New England Journal of Medicine.
04 June, 2013
Atopix Therapeutics Ltd (“Atopix”), a biopharmaceutical company developing a novel class of anti-allergic medicines, has been awarded a £1.7 million grant from the UK Biomedical Catalyst fund to pursue development of OC459 in the treatment of moderate-to-severe atopic dermatitis (a form of eczema).
03 June, 2013